177lu-psma-617
novartis
[' vision']
dr. nilton vaishampayan updated the results of ph3 vision trial (lu177 psma vs soc) with subgroup analysis. overall lu177 psma benefited all subgroups. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer